Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19

P

Postgraduate Institute of Medical Education and Research

Status

Completed

Conditions

Covid19

Treatments

Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO

Study type

Observational

Funder types

Other

Identifiers

NCT04534712
yet to be assigned

Details and patient eligibility

About

Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of population in a Chinese province, soon emerged as a pandemic, causing a huge strain on healthcare system and mortality all over the world. An ideal marker for predicting course of this illness should be easily available and reproducible; as the disease burden has spread to third world countries whose healthcare system is resource limited. Our study is aimed to study the utility of lymphocyte- monocyte ratio in the early stages to predict the progression of COVID 19 pneumonia.

Enrollment

100 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All adults of age 18-80 years tested positive for SARS-CoV-2 reverse-transcriptase - polymerase chain reaction (rt-PCR) and presented within 7 days of symptom(s) onset

Exclusion criteria

  • Pregnancy
  • Sepsis
  • Malignancy
  • Patients on immunosuppressant therapy
  • Chronic inflammatory conditions
  • Cases lost to follow up

Trial design

100 participants in 2 patient groups

PROGRESSION
Description:
Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
Treatment:
Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO
NON PROGRESSION
Description:
Cohort B with those who improved by two points on the ordinal scale without any further progression
Treatment:
Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems